Dr. Vadim S Koshkin, MD
Claim this profileUniversity of California, San Francisco
Studies Bladder Cancer
Studies Prostate Cancer
2 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Vadim S Koshkin, MD is currently running
Enfortumab Vedotin + Pembrolizumab + Radiotherapy
for Bladder Cancer
This phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therapy for treating patients with muscle invasive bladder cancer. Standard of care treatment for muscle invasive bladder cancer is chemotherapy, to shrink the tumor before the main treatment is given (neoadjuvant), followed by surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). In cases where patients are not candidates for the standard of care approach or prefer a bladder sparing option, tri-modality therapy with transurethral resection of bladder tumor (TURBT) followed by combined chemotherapy and radiation therapy is used. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Giving enfortumab vedotin with pembrolizumab and radiation therapy may work better in treating patients with muscle invasive bladder cancer.
Recruiting1 award Phase 1 & 28 criteria
Abemaciclib + Radioligand Therapy
for Prostate Cancer
This trial tests if taking abemaciclib before using 177Lu-PSMA-617 can better treat prostate cancer that has spread and doesn't respond to usual treatments. Abemaciclib slows down cancer growth, and 177Lu-PSMA-617 uses radiation to kill the cancer cells. 177Lu-PSMA-617 targets a specific protein in prostate cancer cells and has shown promising results in treating advanced prostate cancer.
Recruiting1 award Phase 1 & 226 criteria
More about Vadim S Koshkin, MD
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Vadim S Koshkin, MD has experience with
- Enfortumab Vedotin
- Intensity Modulated Radiation Therapy (IMRT)
- Pembrolizumab
- Abemaciclib
- Lutetium Lu 177-PSMA-617
Breakdown of trials Vadim S Koshkin, MD has run
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Vadim S Koshkin, MD specialize in?
Vadim S Koshkin, MD focuses on Bladder Cancer and Prostate Cancer. In particular, much of their work with Bladder Cancer has involved treating patients, or patients who are undergoing treatment.
Is Vadim S Koshkin, MD currently recruiting for clinical trials?
Yes, Vadim S Koshkin, MD is currently recruiting for 2 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that Vadim S Koshkin, MD has studied deeply?
Yes, Vadim S Koshkin, MD has studied treatments such as Enfortumab Vedotin, Intensity Modulated Radiation Therapy (IMRT), Pembrolizumab.
What is the best way to schedule an appointment with Vadim S Koshkin, MD?
Apply for one of the trials that Vadim S Koshkin, MD is conducting.
What is the office address of Vadim S Koshkin, MD?
The office of Vadim S Koshkin, MD is located at: University of California, San Francisco, San Francisco, California 94143 United States. This is the address for their practice at the University of California, San Francisco.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.